Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effect of Dapagliflozin on Patients With Cardiomyopathy
NCT07076615Phase 4Completed
- Start
- Aug 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in heart failure (HF) (2 arms). Primary endpoint: Pulmonary Congestion Assessed by Lung Ultrasound (LUS) at 7 days. Started Aug 2025; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07076615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076615.